Figure 7
Effect of gold nanoconjugates in the presence of 5-ALA mediated PDT targeting MCF-7 (a-c) and MDA-MB-231 (d–f) breast cancer cells. (a) Control (untreated cells). (b) IR-5-ALA-TPP-CTAC©AuNTs (IC50–0.71 ± 0.14 µg/mL). (c) IR-5-ALA-TPP-PSS@CTAC©AuNTs (IC50-0.67 ± 0.89 µg/mL). (d) Control (untreated cells). (e) IR-5-ALA-TPP-CTAC©AuNTs (IC50-0.78 ± 0.55 µg/mL). (f) IR-5-ALA-TPP-PSS@CTAC©AuNTs (IC50-0.58 ± 0.23 µg/mL).
